可切除脑转移瘤术前立体定向放射外科治疗后进展与毒性反应的危险因素
这项国际多中心队列研究纳入8家机构404例实体瘤脑转移患者(416个切除病灶),评估术前立体定向放射外科(SRS)的结局与预后因素。2年瘤腔局部复发率13.7%、脑膜病5.8%、任何级别不良放射效应7.4%,中位总生存17.2个月(95%CI 14.1-21.3个月)。多种肿瘤和治疗因素与上述结局相关。
要点
- 术前SRS后2年瘤腔局部复发率13.7%、脑膜病5.8%、任何级别不良放射效应7.4%。
- 中位总生存17.2个月(95%CI 14.1-21.3个月)。
- 全身疾病状态、切除范围、原发肿瘤类型与总生存最强相关。
核心结论
- 该队列研究中术前SRS后瘤腔局部复发、不良放射效应和脑膜病发生率均较低。
- 识别出多个与瘤腔局部复发、不良放射效应、脑膜病和总生存相关的肿瘤及治疗因素。
- 术前与术后SRS的3期随机临床试验(NRG BN012,NCT05438212)已开始入组。
研究设计与样本
- 国际多中心队列研究(Preoperative Radiosurgery for Brain Metastases-PROPS-BM),纳入8家机构中至少1个病灶接受术前SRS并计划切除的实体瘤脑转移患者。
- 允许对同步未切除脑转移灶行放射外科;排除既往或计划全脑放疗及无颅脑影像随访者。
- 患者治疗时间为2005年至2021年,大多数在2017年至2021年治疗。
- 术前SRS中位剂量为1次15 Gy或3次24 Gy,于切除前中位(IQR)2(1-4)天实施。
- 共纳入404例患者(214例女性[53%];中位[IQR]年龄60.6[54.0-69.6]岁),416个切除索引病灶。
主要发现
- 2年瘤腔局部复发率为13.7%。
- 全身疾病状态、切除范围、SRS分次方案、手术方式(分块与整块)及原发肿瘤类型与瘤腔局部复发风险相关。
- 2年脑膜病率为5.8%,切除范围、原发肿瘤类型及后颅窝位置与脑膜病风险相关。
- 2年任何级别不良放射效应率为7.4%,靶区外扩大于1 mm及黑色素瘤原发与不良放射效应风险相关。
- 中位总生存为17.2个月(95%CI 14.1-21.3个月),全身疾病状态、切除范围及原发肿瘤类型是与总生存最强相关的预后因素。
关键数值与推荐
- 术前SRS中位剂量为1次15 Gy或3次24 Gy。
- 2年瘤腔局部复发率13.7%。
- 2年脑膜病率5.8%。
- 2年任何级别不良放射效应率7.4%。
- 中位总生存17.2个月(95%CI 14.1-21.3个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Preoperative stereotactic radiosurgery (SRS) has been demonstrated as a feasible alternative to postoperative SRS for resectable brain metastases (BMs) with potential benefits in adverse radiation effects (AREs) and meningeal disease (MD). However, mature large-cohort multicenter data are lacking. OBJECTIVE: To evaluate preoperative SRS outcomes and prognostic factors from a large international multicenter cohort (Preoperative Radiosurgery for Brain Metastases-PROPS-BM). DESIGN, SETTING, AND PARTICIPANTS: This multicenter cohort study included patients with BMs from solid cancers, of which at least 1 lesion received preoperative SRS and a planned resection, from 8 institutions. Radiosurgery to synchronous intact BMs was allowed. Exclusion criteria included prior or planned whole-brain radiotherapy and no cranial imaging follow-up. Patients were treated between 2005 and 2021, with most treated between 2017 and 2021. EXPOSURES: Preoperative SRS to a median dose to 15 Gy in 1 fraction or 24 Gy in 3 fractions delivered at a median (IQR) of 2 (1-4) days before resection. MAIN OUTCOMES AND MEASURES: The primary end points were cavity local recurrence (LR), MD, ARE, overall survival (OS), and multivariable analysis of prognostic factors associated with these outcomes. RESULTS: The study cohort included 404 patients (214 women [53%]; median [IQR] age, 60.6 [54.0-69.6] years) with 416 resected index lesions. The 2-year cavity LR rate was 13.7%. Systemic disease status, extent of resection, SRS fractionation, type of surgery (piecemeal vs en bloc), and primary tumor type were associated with cavity LR risk. The 2-year MD rate was 5.8%, with extent of resection, primary tumor type, and posterior fossa location being associated with MD risk. The 2-year any-grade ARE rate was 7.4%, with target margin expansion greater than 1 mm and melanoma primary being associated with ARE risk. Median OS was 17.2 months (95% CI, 14.1-21.3 months), with systemic disease status, extent of resection, and primary tumor type being the strongest prognostic factors associated with OS. CONCLUSIONS AND RELEVANCE: In this cohort study, the rates of cavity LR, ARE, and MD after preoperative SRS were found to be notably low. Several tumor and treatment factors were identified that are associated with risk of cavity LR, ARE, MD, and OS after treatment with preoperative SRS. A phase 3 randomized clinical trial of preoperative vs postoperative SRS (NRG BN012) has began enrolling (NCT05438212).
引用
- Prabhu RS, Akinyelu T, Vaslow ZK, et al. Risk Factors for Progression and Toxic Effects After Preoperative Stereotactic Radiosurgery for Patients With Resected Brain Metastases. JAMA Oncol. 2023. PMID: 37289451. doi:10.1001/jamaoncol.2023.1629
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。